News | June 15, 2024
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
There was no observation related to data integrity reported
Accelerating sustainability in Indian pharma industry
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
This strategic decision will unlock significant value for our scientific and industrial products business
Subscribe To Our Newsletter & Stay Updated
